Skip To Main Content
Jessica Langbaum on Muck Rack

Jessica Langbaum

Phoenix
As seen in: HuffPost, JAMA (The Journal of the American Medical Association), AZCentral | The Arizona Republic, The Lancet, NeurologyLive, Alzheimer's & Dementia, Life Science Leader
We thank you for your support in ending Alzheimer’s, join us at @AlzRegistry for continued ways to get involved.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jessica

Contact Jessica, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clarifications on our Policy View

|
By Eric M Reiman, Robert Alexander, Jessica Langbaum
| The Lancet Verified
Affiliations & Notes aBanner Alzheimer's Institute, Phoenix, AZ 85006, USA bChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV, USA Article Info Publication History: Published February 27, 2026 DOI: 10.1016/S1474-4422(26)00089-X External LinkAlso available on ScienceDirect External Link Copyright: © 2026 Elsevier Ltd.
Open in Who Shared Issue with article?

A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

|
By Eric M Reiman, Robert Alexander, Jessica Langbaum
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. 2025 Alzheimer's disease facts and figures Alzheimers Dement. 2025; 21, e70235 2. Jack, Jr, CR ∙ Andrews, JS ∙ Beach, TG ∙ et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Alzheimers Dement. 2024; 20:5143-5169 3. van Dyck, CH ∙ Swanson, CJ ∙ Aisen, P ∙ et al. Lecanemab in early Alzheimer's disease N Engl J Med. 2023; 388:9-21 4.
Open in Who Shared Issue with article?

Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1

|
By Jessica Langbaum, Angela Bradbury, Brian L. Egleston, Elisabeth McCarty Wood
| The Lancet Verified
Introduction The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset Alzheimer’s disease.1,2 Disclosing APOE genotype is increasingly part of clinical care for people with cognitive impairment.3 With recent approvals of lecanemab and donanemab by the US Food and Drug Administration (FDA), there will be a large increase in APOE disclosure to guide clinical decision making, as Appropriate Use Recommendations4,5 include informing patients of their risk of...
Open in Who Shared Issue with article?
See all 11 licensed articles (18 Total)